① Side effect data in Japan is not centrally managed, so data from the PMDA (equivalent to the FDA) is used.
② The data collector is someone from Meiji Seika Pharma (the company that sells Replicon).
③ A Weibull distribution is fitted to the side effect distribution.
Due to ①, the side effect data is much lower than the actual number of side effects.
② There is a conflict of interest in selling Replicon.
③ The Weibull dist. is a distribution function used to estimate the initial failure and wear limit of machines. People ≠ machine. Therefore, medium to long-term side effects in humans are ignored.
Therefore, there is a clear intention to conceal side effects for most of one's life by only estimating those occurring immediately after vaccination and towards the end of life.
There are problems with the original paper.
① Side effect data in Japan is not centrally managed, so data from the PMDA (equivalent to the FDA) is used.
② The data collector is someone from Meiji Seika Pharma (the company that sells Replicon).
③ A Weibull distribution is fitted to the side effect distribution.
Due to ①, the side effect data is much lower than the actual number of side effects.
② There is a conflict of interest in selling Replicon.
③ The Weibull dist. is a distribution function used to estimate the initial failure and wear limit of machines. People ≠ machine. Therefore, medium to long-term side effects in humans are ignored.
Therefore, there is a clear intention to conceal side effects for most of one's life by only estimating those occurring immediately after vaccination and towards the end of life.